 |
|
Lipid-Lowering Therapy and Risk of Coronary Events
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The authors of ALLHAT-LLT1 explored several possible reasons for the failure of lipid-lowering therapy to translate into any change in the risk of CHD. It is possible, however, that there may be a threshold value of the total cholesterol/HDL-C (high-density lipoprotein cholesterol) ratio, below which further lowering will not produce any significant reduction in CHD.2 The average baseline ratios in several studies were greater than 5, which may be a critical value. Following treatment there was a significant reduction in CHD, especially in those studies that reported a ratio less than 5. Particularly noteworthy were the VA-HIT results, in which gemfibrozil produced a 24% decrease in CHD yet had no effect on LDL-C levels.3 The baseline ratio in ALLHAT-LLT was 4.67, so it is not surprising that further lowering of the ratio offered no CHD benefit. In the BIP study,4 a 41% reduction in CHD occurred in . . . [Full Text of this Article]
RELATED ARTICLES
Lipid-Lowering Therapy and Risk of Coronary Events
William C. Taylor
JAMA. 2003;289(16):2070.
EXTRACT
| FULL TEXT
Lipid-Lowering Therapy and Risk of Coronary Events
John A. Blakely
JAMA. 2003;289(16):2070-2071.
EXTRACT
| FULL TEXT
Lipid-Lowering Therapy and Risk of Coronary Events
Luca Mascitelli and Francesca Pezzetta
JAMA. 2003;289(16):2071.
EXTRACT
| FULL TEXT
Lipid-Lowering Therapy and Risk of Coronary Events—Reply
Jeffrey L. Probstfield
JAMA. 2003;289(16):2071-2072.
EXTRACT
| FULL TEXT
Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2998-3007.
ABSTRACT
| FULL TEXT
|
